US-FED-00000384524 - OLINK EXPLORE HT SERVICES - Deadline July 9,2026

Background Information: Myelodysplastic Syndromes are heterogeneous stem cell malignancies characterized by chronic inflammation, peripheral cytopenias, and bone marrow dysplasia. LRBGE preliminary data from targeted proteomic arrays has identified substantial changes in the proteome, including secreted proteins in bone marrow plasma from these patients, that may contribute to disease progression. The program has received Bench to Bedside funding to further interrogate these proteomic changes and identify disease biology and potential therapeutic vulnerabilities.The Olink Explore HT platform is required because it provides high–throughput, multiplexed protein detection using low–volume primary specimens. Olink is the proprietary manufacturer of the Olink Explore HT platform and associated plates. Although third–party service contractors may theoretically offer related sample–processing support, they would not provide the same Olink Explore HT analysis workflow and may be more expensive while not delivering the same analysis, comparability, or direct platform support required for this project